

PathoGenesis Corporation

[View the current PathoGenesis Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8110-PathoGenesis+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/8110-PathoGenesis+Corporation.html>)

Contact Details:

201 Elliott Avenue W. Suite 150
Seattle
Washington
98119
United States of America

Tel: 206 467 8100
Fax: 206 270 3313
Email:

PathoGenesis Corporation develops and markets novel drugs to treat serious, chronic human infectious diseases where there is a significant need for improved therapy. In December 1997, the U. S. Food and Drug Administration approved our first drug, TOBI (tobramycin solution for inhalation). TOBI is indicated for the management of cystic fibrosis (CF) patients with *Pseudomonas aeruginosa* lung infections. PathoGenesis Corporation began marketing TOBI in 1998 in the U.S., and generated \$60.7 million in sales during the year. TOBI was approved for sale in Canada and Argentina in February 1999. PathoGenesis Corporation have filed for regulatory approvals in Europe and Australia. Applications in other countries are pending.

Recent Publications by PathoGenesis Corporation:



- [Envelope vaccination shapes viral envelope evolution following SIV infection in rhesus monkeys.](#)
*The evolution of envelope mutations by replicating primate...*13th November, 2009
Division of Viral Pathogenesis, Department of Medicine, Beth Israel- J Virol. 2009 Nov 11. ([DOI Direct Link](#))
- [The BosR regulatory protein of *Borrelia burgdorferi* interfaces with the RpoS regulatory pathway and modulates both the oxidative stress response and pathogenic properties of the Lyme disease spirochete.](#)
*Borrelia burgdorferi, the Lyme disease spirochete, adapts as it moves...*13th November, 2009
Department of Microbial and Molecular Pathogenesis, College of Medicine,- Mol Microbiol. 2009 Nov 10. ([DOI Direct Link](#))
- [Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?](#)
*Group A streptococcus (GAS) is a bacterial pathogen responsible for a wide...*13th November, 2009
Bacterial Pathogenesis Laboratory, Queensland Institute of Medical- Expert Rev Vaccines. 2009 Nov

11. ([DOI Direct Link](#))
- [N-linked glycan-dependent interaction of CD63 with CXCR4 at the Golgi apparatus induces downregulation of CXCR4.](#)
ABSTRACT Efficient downregulation of CXCR4 cell surface expression by... 12th November, 2009
 Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto- Microbiol Immunol. 2009 Nov;53(11):629-35. ([DOI Direct Link](#))
 - [Determinants of survival in progressive multifocal leukoencephalopathy.](#)
BACKGROUND: We sought to characterize the role of immunologic, virologic,... 11th November, 2009
 Division of Viral Pathogenesis, BIDMC, Harvard Medical School, Boston, MA- Neurology. 2009 Nov 10;73(19):1551-8. ([DOI Direct Link](#))
 - [A novel class of meso-tetrakis-porphyrin derivatives exhibit potent activities against hepatitis C virus genotype 1b replicons in vitro.](#)
Recent years have seen the rapid advancement of new therapeutic agents... 11th November, 2009
 Department of Pharmacology, Yale University School of Medicine, New Haven,- Antimicrob Agents Chemother. 2009 Nov 9. ([DOI Direct Link](#))
 - [Polar localization of the CckA histidine kinase and cell cycle periodicity of the essential master regulator CtrA in Caulobacter crescentus.](#)
The phosphorylated form of the response regulator CtrA represses DNA... 10th November, 2009
 Department of Molecular, Cellular and Developmental Biology, Yale- J Bacteriol. 2009 Nov 6. ([DOI Direct Link](#))
 - [Novel metal-binding site of Pseudomonas reinekei MT1 trans-dienelactone hydrolase.](#)
Pseudomonasreinekei MT1 is capable of growing on 4- and 5-chlorosalicylate... 10th November, 2009
 Division of Microbial Pathogenesis, HZI - Helmholtz Centre for Infection- Biochem Biophys Res Commun. 2009 Nov 4. ([DOI Direct Link](#))
 - [Viral Genetic Determinants of Nonprogressive HIV Type 1 Subtype C Infection in Antiretroviral Drug-Naive Children.](#)
Abstract Characterization of HIV-1 from slow progressors is important to... 10th November, 2009
 1 HIV Pathogenesis Research Laboratory, Department of Molecular Medicine- AIDS Res Hum Retroviruses. 2009 Nov 6. ([DOI Direct Link](#))
 - [Bisphosphonate-Related Osteonecrosis of the Jaw: The Role of Actinomyces.](#)
The etiology of bisphosphonate-related osteonecrosis of the jaw is unknown... 6th November, 2009
 Veterans Administration Western New York Healthcare System, 2Department of- Clin Infect Dis. 2009 Nov 3. ([DOI Direct Link](#))
 - [Biologic Activities of the TolC-like Protein of Neisseria meningitidis as Assessed by Functional Complementation in Escherichia coli.](#)
Neisseria meningitidis can produce a TolC-like protein needed for... 4th November, 2009
 Department of Microbiology and Immunology, Emory University School of- Antimicrob Agents Chemother. 2009 Nov 2. ([DOI Direct Link](#))
 - [Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas.](#)
PURPOSE: Thymomas and thymic carcinomas are rare intrathoracic... 29th October, 2009
 Authors' Affiliations: Human Oncology and Pathogenesis Program (HOPP);- Clin Cancer Res. 2009 Oct 27. ([DOI Direct Link](#))
 - [Characterization of a Conditional bosR Mutant in Borrelia burgdorferi.](#)
Borrelia burgdorferi, the etiological agent of Lyme disease, adapts to... 28th October, 2009
 Department of Microbial and Molecular Pathogenesis and Systems Biology and- Infect Immun. 2009 Oct 26. ([DOI Direct Link](#))
 - [Acid phosphatases do not contribute to pathogenesis of Type A Francisella tularensis.](#)
The intracellular pathogen Francisella tularensis is the causative agent... 28th October, 2009
 Tularemia Pathogenesis Section, Laboratory of Intracellular Parasites and- Infect Immun. 2009 Oct 26. ([DOI Direct Link](#))
 - [Lung cancer profiling: Genetic and molecular predictors of MEK-dependence.](#)
The intracellular pathogen Francisella tularensis is the causative agent... 27th October, 2009

Press Releases on PathoGenesis Corporation:

Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference	20th November, 2009	Centene Corporation	ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3,
Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,
Reportlinker Adds Medical Adhesives and Sealants - A US Market Review	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Medical Adhesives and Sealants - A US Market Review http://www
Reportlinker Adds Toothpaste - Global Market Trends	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Toothpaste - Global Market Trends http://www.reportlinker.com/p0164389
Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to

BioNews Results for PathoGenesis Corporation



- [Pathogenesis of inflammatory bowel disease \(IBD\)](#)
MDLinx: Nov 11 2009 10:59AM Matching: pathogenesis
- [Medical News: New Three-Year Grant From The Bill & Melinda Gates Foundation Announced By Keystone Symposia](#)
BioFind: Nov 9 2009 1:32PM Matching: pathogenesis
- [Medical News: New Three-Year Grant From The Bill & Melinda Gates Foundation Announced By](#)

[Keystone Symposia](#)

BioFind: Nov 9 2009 1:31PM Matching: pathogenesis

- [New Three-Year Grant From The Bill & Melinda Gates Foundation Announced By Keystone Symposia](#)
Medical News Today: Nov 9 2009 9:38AM Matching: pathogenesis
- [Juvenile Dermatomyositis: Advances in Pathogenesis, Evaluation, and Treatment](#)
MDLinx: Nov 9 2009 11:53AM Matching: pathogenesis
- [Pathogenesis similarities seen in early onset, adult IBD](#)
SmartBrief: Nov 6 2009 7:27PM Matching: pathogenesis
- [Inflammation in the Intestinal Tract: Pathogenesis and Treatment](#)
MDLinx: Nov 6 2009 1:20PM Matching: pathogenesis
- [Research and Markets: Annals of the New York Academy of Sciences, Immunology of Diabetes V](#)
RBC Dain Rauscher: Nov 5 2009 6:35PM Matching: pathogenesis
- [Leprosy: Man's persistent companion](#)
News-Medical.Net: Nov 4 2009 8:53AM Matching: pathogenesis
- [Mankind And Leprosy Bacteria](#)
Medical News Today: Nov 3 2009 4:43PM Matching: pathogenesis
- [Medical News: Mankind And Leprosy Bacteria](#)
Medical News Today: Nov 3 2009 3:52PM Matching: pathogenesis
- [Medical News: Mankind And Leprosy Bacteria](#)
Medical News Today: Nov 3 2009 3:51PM Matching: pathogenesis
- [The entwined destinies of mankind and leprosy bacteria](#)
Research & Development: Nov 2 2009 4:57PM Matching: pathogenesis
- [Familial Tumoral Calcinosis: From Characterization of a Rare Phenotype to the Pathogenesis of Ectopic Calcification](#)
MDLinx: Oct 30 2009 10:33AM Matching: pathogenesis
- [Familial Tumoral Calcinosis: From Characterization of a Rare Phenotype to the Pathogenesis of Ectopic Calcification](#)
Journal of Investigative Dermatology: Oct 29 2009 10:51AM Matching: pathogenesis

PathoGenesis Corporation Patents:



- 6087358- [Nitro-\[2,1-b\]imidazopyran compounds and antibacterial uses thereof](#)
- 5441955- [Indolo\[2,1-b\]quinazoline-6,12-dione antibacterial compounds and methods of use thereof](#)
- 5508269- [Aminoglycoside formulation for aerosolization](#)
- 5668127- [Nitroimidazole antibacterial compounds and methods of use thereof](#)
- 5679515- [Mycobacterial reporter strains and uses thereof](#)
- 5700683- [Virulence-attenuating genetic deletions deleted from mycobacterium BCG](#)
- 5716584- [Device for the synthesis of compounds in an array](#)
- 5759780- [Methods for enriching target nucleic acid sequences](#)
- 5767068- [Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections](#)
- 6083922- [Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis](#)
- 5399558- [Isoflavonoid antibacterial compounds, compositions and use](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

